Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses

Abstract Avian influenza A(H7N9) epidemics have a fatality rate of approximately 40%. Previous studies reported that low pathogenic avian influenza (LPAI)-derived candidate vaccine viruses (CVVs) are poorly immunogenic. Here, we assess the immunogenicity and efficacy of a highly pathogenic avian inf...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peter Radvak, Martina Kosikova, Yuan-Chia Kuo, Xing Li, Richard Garner, Falko Schmeisser, Ivan Kosik, Zhiping Ye, Jerry P. Weir, Jonathan W. Yewdell, Hang Xie
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/44f77440cac7414993426f82d53e2eb9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44f77440cac7414993426f82d53e2eb9
record_format	dspace
spelling	oai:doaj.org-article:44f77440cac7414993426f82d53e2eb92021-12-02T18:01:29ZHighly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses10.1038/s41541-021-00295-72059-0105https://doaj.org/article/44f77440cac7414993426f82d53e2eb92021-02-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00295-7https://doaj.org/toc/2059-0105Abstract Avian influenza A(H7N9) epidemics have a fatality rate of approximately 40%. Previous studies reported that low pathogenic avian influenza (LPAI)-derived candidate vaccine viruses (CVVs) are poorly immunogenic. Here, we assess the immunogenicity and efficacy of a highly pathogenic avian influenza (HPAI) A/Guangdong/17SF003/2016 (GD/16)-extracted hemagglutinin (eHA) vaccine. GD/16 eHA induces robust H7-specific antibody responses in mice with a marked adjuvant antigen-sparing effect. Mice immunized with adjuvanted GD/16 eHA are protected from the lethal LPAI and HPAI H7N9 challenges, in stark contrast to low antibody titers and high mortality in mice receiving adjuvanted LPAI H7 eHAs. The protection correlates well with the magnitude of the H7-specific antibody response (IgG and microneutralization) or HA group 2 stem-specific IgG. Inclusion of adjuvanted GD/16 eHA in heterologous prime-boost improves the immunogenicity and protection of LPAI H7 HAs in mice. Our findings support the inclusion of GD/16-derived CVV in the pandemic preparedness vaccine stockpile.Peter RadvakMartina KosikovaYuan-Chia KuoXing LiRichard GarnerFalko SchmeisserIvan KosikZhiping YeJerry P. WeirJonathan W. YewdellHang XieNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Peter Radvak Martina Kosikova Yuan-Chia Kuo Xing Li Richard Garner Falko Schmeisser Ivan Kosik Zhiping Ye Jerry P. Weir Jonathan W. Yewdell Hang Xie Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
description	Abstract Avian influenza A(H7N9) epidemics have a fatality rate of approximately 40%. Previous studies reported that low pathogenic avian influenza (LPAI)-derived candidate vaccine viruses (CVVs) are poorly immunogenic. Here, we assess the immunogenicity and efficacy of a highly pathogenic avian influenza (HPAI) A/Guangdong/17SF003/2016 (GD/16)-extracted hemagglutinin (eHA) vaccine. GD/16 eHA induces robust H7-specific antibody responses in mice with a marked adjuvant antigen-sparing effect. Mice immunized with adjuvanted GD/16 eHA are protected from the lethal LPAI and HPAI H7N9 challenges, in stark contrast to low antibody titers and high mortality in mice receiving adjuvanted LPAI H7 eHAs. The protection correlates well with the magnitude of the H7-specific antibody response (IgG and microneutralization) or HA group 2 stem-specific IgG. Inclusion of adjuvanted GD/16 eHA in heterologous prime-boost improves the immunogenicity and protection of LPAI H7 HAs in mice. Our findings support the inclusion of GD/16-derived CVV in the pandemic preparedness vaccine stockpile.
format	article
author	Peter Radvak Martina Kosikova Yuan-Chia Kuo Xing Li Richard Garner Falko Schmeisser Ivan Kosik Zhiping Ye Jerry P. Weir Jonathan W. Yewdell Hang Xie
author_facet	Peter Radvak Martina Kosikova Yuan-Chia Kuo Xing Li Richard Garner Falko Schmeisser Ivan Kosik Zhiping Ye Jerry P. Weir Jonathan W. Yewdell Hang Xie
author_sort	Peter Radvak
title	Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
title_short	Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
title_full	Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
title_fullStr	Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
title_full_unstemmed	Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
title_sort	highly pathogenic avian influenza a/guangdong/17sf003/2016 is immunogenic and induces cross-protection against antigenically divergent h7n9 viruses
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/44f77440cac7414993426f82d53e2eb9
work_keys_str_mv	AT peterradvak highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses AT martinakosikova highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses AT yuanchiakuo highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses AT xingli highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses AT richardgarner highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses AT falkoschmeisser highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses AT ivankosik highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses AT zhipingye highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses AT jerrypweir highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses AT jonathanwyewdell highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses AT hangxie highlypathogenicavianinfluenzaaguangdong17sf0032016isimmunogenicandinducescrossprotectionagainstantigenicallydivergenth7n9viruses
_version_	1718378984815722496

Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses

Ejemplares similares